Kirkland Counsels Heron Therapeutics on Cooperation Agreement with Rubric Capital and Velan Capital
Kirkland & Ellis advised Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, on a cooperation agreement with two of its shareholders, Rubric Capital and Velan Capital. As part of the agreement, Heron will add new independent directors to its board and Rubric and Velan agreed to certain standstill and voting commitments.
The Kirkland team was led by corporate partners Shaun Mathew and Daniel Wolf and associates Frank Liu and Alex Adamis.
